Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Signs of dangerous internal bleeding while taking Eliquis (apixaban) include red, pink, or brown urine, black or tarry stools, vomiting blood or material that looks like coffee grounds, coughing up blood, and unusual bruising or swelling. Bleeding in the brain may cause sudden severe headache, confusion, vision changes, weakness, or trouble speaking, while unexplained dizziness, fainting, extreme fatigue, shortness of breath, or abdominal or joint pain can signal hidden blood loss. Any bleeding that will not stop after 10 minutes of pressure, or that follows a fall or head injury, needs emergency evaluation even if you feel fine. Several factors change your risk, including your dose, kidney function, age, and other medications such as NSAIDs or aspirin, so see below to understand more.
If you are noticing symptoms that could point to bleeding, guessing is the riskiest option, since internal bleeding on a blood thinner can worsen quickly and quietly. Take a free, instant, online symptom check to help clarify what your symptoms may mean and decide whether to call your prescriber or seek urgent care now.
Last reviewed for medical accuracy: 09/12/2026
Eliquis (apixaban) is a widely prescribed blood thinner used to reduce the risk of stroke and blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism. As with any anticoagulant, Eliquis side effects can include bleeding. Most bleeding is minor—like easy bruising or nosebleeds—but on rare occasions, internal bleeding can be serious or life threatening. Recognizing early warning signs and seeking prompt care can make all the difference.
Blood thinners work by interfering with your body’s ability to form clots. While this prevents harmful clots, it also raises the risk that bleeding won’t stop on its own. Internal bleeding isn’t always obvious. It can develop gradually or suddenly, depending on the location and cause. Untreated, significant blood loss can lead to:
Early detection and treatment help prevent complications.
Below are warning signs you should never ignore. If you experience any of these, seek medical attention immediately.
Bleeding in the stomach or intestines may cause:
Although rare, bleeding in or around the brain is a medical emergency. Watch for:
Blood in the urine or around reproductive organs can signal bleeding:
Bleeding into muscles or joints may show up as:
Blood in the lungs can be life threatening. Look for:
In addition to site-specific symptoms, these general signs may indicate serious bleeding:
If you notice a combination of these symptoms, treat it as an emergency.
Sharing clear information helps your care team respond quickly and effectively.
While you can’t eliminate all risk, these steps reduce your chance of dangerous bleeding:
Some bleeding may appear minor but can mask something serious. Always reach out if you notice:
For concerns that feel urgent—but not yet life threatening—you can also try a free, online symptom check, using the doctor approved Ubie Symptom Checker to guide your next steps.
Your health matters. Never hesitate to seek help for bleeding that feels out of the ordinary or severe. Always speak to a doctor about anything life threatening or serious.
(References)
* Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27. PMID: 21870978.
* Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8. PMID: 23216615.
* Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1. PMID: 23808982.
* Kuno T, Takagi H, Ando T, Sugiyama T, Miyashita S, Valentin N, Shimada YJ, Kodaira M, Numasawa Y, Briasoulis A, Burger A, Bangalore S. Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am Coll Cardiol. 2020 Jan 28;75(3):273-285. doi: 10.1016/j.jacc.2019.10.059. PMID: 31976865.
* Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M, Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Apr 23;382(17):1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29. PMID: 32223112.
* Mamas MA, Batson S, Pollock KG, Grundy S, Matthew A, Chapman C, Manuel JA, Farooqui U, Mitchell SA. Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation. Am J Cardiol. 2022 Mar 1;166:58-64. doi: 10.1016/j.amjcard.2021.11.021. Epub 2021 Dec 20. PMID: 34949473.
* Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia DA, Garonzik S, Lopes RD, Mahaffey KW, Matsuda K, Middleton JP, Rymer JA, Sands GH, Thadhani R, Thomas KL, Washam JB, Winkelmayer WC, Granger CB, RENAL-AF Investigators. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation. 2022 Dec 6;146(23):1735-1745. doi: 10.1161/CIRCULATIONAHA.121.054990. Epub 2022 Nov 6. PMID: 36335914.
* Payne RM, Burns KM, Glatz AC, Male C, Donti A, Brandão LR, Balling G, VanderPluym CJ, Bu'Lock F, Kochilas LK, Stiller B, Cnota JF 2nd, Rahkonen O, Khan A, Adorisio R, Stoica S, May L, Burns JC, Saraiva JFK, McHugh KE, Kim JS, Rubio A, Chía-Vazquez NG, Meador MR, Dyme JL, Reedy AM, Ajavon-Hartmann T, Jarugula P, Carlson-Taneja LE, Mills D, Wheaton O, Monagle P. Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease. J Am Coll Cardiol. 2023 Dec 12;82(24):2296-2309. doi: 10.1016/j.jacc.2023.10.010. PMID: 38057072.
* Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, Ma CS, Goodman SG, Oldgren J, Hammett C, Lopes RD, Akao M, De Caterina R, Kirchhof P, Gorog DA, Hemels M, Rienstra M, Jones WS, Harrington J, Lip GYH, Ellis SJ, Rockhold FW, Neumann C, Alexander JH, Viethen T, Hung J, Coppolecchia R, Mundl H, Caso V, OCEANIC-AF Steering Committee and Investigators. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2025 Jan 2;392(1):23-32. doi: 10.1056/NEJMoa2407105. Epub 2024 Sep 1. PMID: 39225267.
* Castellucci LA, Chen VM, Kovacs MJ, Lazo-Langner A, Greenstreet P, Kahn S, Côté B, Schulman S, de Wit K, Douketis J, Suryanarayan D, Wan T, Yeo E, Le Templier G, Tran HA, Willcox A, Crowther HJ, Prasad R, Shivakumar S, Umana E, Ni Ainle F, Tritschler T, Barco S, Galanaud JP, Blondon M, Baumann Kreuziger L, Solymoss S, Kearon C, Thomas E, Ramsay T, Le Gal G, Rodger M, COBRRA Trial Investigators. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. N Engl J Med. 2026 Mar 12;394(11):1051-1060. doi: 10.1056/NEJMoa2510703. PMID: 41812192.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.